ReviewAnnals of medicine and surgery (2012)2025
The clinical implications of zinc and copper levels in COPD patients: a narrative review.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nutrition in the prevention and treatment of pelvic inflammatory disease: a review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD), a leading cause of global morbidity and the third leading cause of death, significantly impairs quality of life. Copper (Cu) and zinc (Zn) are critical micronutrients that support antioxidant defense, immune function, and inflammation regulation, processes critical to COPD pathology. This review investigates evidence linking serum Cu and Zn levels to COPD severity, progression, and exacerbation. Elevated Cu and Zn levels, along with the Cu/Zn ratio, correlate with COPD exacerbation and may serve as prognostic and diagnostic biomarkers by reflecting inflammatory and oxidative stress pathways. However, well-designed clinical trials are needed to confirm their impact on COPD outcomes. This review clarifies the clinical role of Cu and Zn in COPD and explores their potential as supplementary treatments to mitigate inflammation and oxidative stress. Future research should focus on their therapeutic applications to improve COPD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.